Cardiovascular outcome trials in patients with chronic kidney disease: Challenges associated with selection of patients and endpoints

European Heart Journal

Volumn 40, Issue 11, 2019, Pages 880-886

  Rossignol, Patrick ^a,b   Agarwal, Rajiv ^c,d   Canaud, Bernard ^e   Charney, Alan ^f   Chatellier, Gilles ^g   Craig, Jonathan C ^h,i   Cushman, William C ^j   Gansevoort, Ronald T ^k   Fellström, Bengt ^l   Garza, Dahlia ^m   Guzman, Nicolas ⁿ   Holtkamp, Frank A ^k,o   London, Gerard M ^b,p   Massy, Ziad A ^b,q   Mebazaa, Alexandre ^b,r,s,t   Mol, Peter G M ^k,o   Pfeffer, Marc A ^u   Rosenberg, Yves ^v   Ruilope, Luis M ^w   Seltzer, Jonathan ^x   Shah, Amil M ^u   Shah, Salim ^y   Singh, Bhupinder ^z   Stefánsson, Bergur V ^aa   Stockbridge, Norman ^ab   Stough, Wendy Gattis ^ac   Thygesen, Kristian ^ad   Walsh, Michael ^ae   Wanner, Christoph ^af   Warnock, David G ^ag   Wilcox, Christopher S ^ah   Wittes, Janet ^ai   Pitt, Bertram ^aj   Thompson, Aliza ^ab   Zannad, Faiez ^a,b   more..

^a UNIVERSITÉ DE LORRAINE   (France)

^b INI CRCT   (France)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d RICHARD L ROUDEBUSH VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e UNIV MONTPELLIER   (France)

^f NOVARTIS PHARMA AG   (Switzerland)

^g HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^h UNIVERSITY OF SYDNEY   (Australia)

ⁱ CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^j VETERANS AFFAIRS MEDICAL CENTER   (United States)

^k UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^l LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^m Vifor (International) Inc   (Switzerland)

ⁿ ASTRAZENECA   (United Kingdom)

^o MEDICINES EVALUATION BOARD   (Netherlands)

^p France Centre Hospitalier FH Manhès   (France)

^q HÔPITAL AMBROISE PARÉ   (France)

^r University of Paris   (France)

^s UNIVERSITÉ PARIS DESCARTES   (France)

^t ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^u HARVARD MEDICAL SCHOOL   (United States)

^v NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^w UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^x ACI Clinical   (United States)

^y Sarfez Pharmaceuticals Inc   (United States)

^z ZS Pharma Inc   (United States)

^aa ASTRAZENECA R AND D   (Sweden)

^ab CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^ac CAMPBELL UNIVERSITY   (United States)

^ad AARHUS UNIVERSITY HOSPITAL   (Denmark)

^ae MCMASTER UNIVERSITY   (Canada)

^af UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^ag University of Alabama at Birmingham   (United States)

^ah GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^ai University of Iowa   (United States)

^aj UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

more..

Author keywords

Cardiovascular diseases; Chronic kidney failure; Chronic renal insufficiency; Clinical trials as topic

Indexed keywords

ALBUMIN; BRAIN NATRIURETIC PEPTIDE; CANAGLIFLOZIN; PLACEBO; PROTEIN; TROPONIN; CREATININE;

ACUTE HEART INFARCTION; ALL CAUSE MORTALITY; ARTICLE; ASSAY; CALCIFICATION PROPENSITY ASSAY; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; DIABETIC NEPHROPATHY; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; END STAGE RENAL DISEASE; HEART FAILURE; HEMODIALYSIS; HUMAN; MORBIDITY; PATIENT SELECTION; PATIENT-REPORTED OUTCOME; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; RENAL CLEARANCE; SURVIVAL; TREATMENT OUTCOME; TREATMENT RESPONSE; BLOOD; CARDIOVASCULAR SYSTEM; CLINICAL TRIAL (TOPIC); COLLABORATIVE LEARNING; COMPLICATION; KIDNEY; METHODOLOGY; PATHOPHYSIOLOGY; PATIENT CARE; PROCEDURES;

CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; CLINICAL TRIALS AS TOPIC; CREATININE; HUMANS; INTERDISCIPLINARY PLACEMENT; KIDNEY; KIDNEY FAILURE, CHRONIC; PATIENT CARE MANAGEMENT; PATIENT SELECTION; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; RESEARCH DESIGN;

EID: 85062883461     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehx209     Document Type: Article

References (32)

1. Tonelli M, Karumanchi SA, Thadhani R. Epidemiology and mechanisms of uremia-related cardiovascular disease. Circulation 2016;133:518-536.
2. Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, Reboussin DM, Rahman M, Oparil S, Lewis CE, Kimmel PL, Johnson KC, Goff DC, Jr, Fine LJ, Cutler JA, Cushman WC, Cheung AK, Ambrosius WT. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 2015;373:2103-2116.
3. Coca SG, Krumholz HM, Garg AX, Parikh CR. Underrepresentation of renal disease in randomized controlled trials of cardiovascular disease. Jama 2006;296:1377-1384.
4. Konstantinidis I, Nadkarni GN, Yacoub R, Saha A, Simoes P, Parikh CR, Coca SG. Representation of patients with kidney disease in trials of cardiovascular interventions: an updated systematic review. JAMA Intern Med 2016;176:121-124.
5. Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, Jafar TH, Heerspink HJ, Mann JF, Matsushita K, Wen CP. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet 2013;382:339-352.
6. Ruiz-Hurtado G, Ruilope LM. Does cardiovascular protection translate into renal protection? Nat Rev Cardiol 2014;11:742-746.
7. Ruiz-Hurtado G, Sarafidis P, Fernandez-Alfonso MS, Waeber B, Ruilope LM. Global cardiovascular protection in chronic kidney disease. Nat Rev Cardiol 2016;13:603-608.
8. Ishida JH, Johansen KL. Exclusion of patients with kidney disease from cardiovascular trials. JAMA Intern Med 2016;176:124-125.
9. Szummer K, Lundman P, Jacobson SH, Schon S, Lindback J, Stenestrand U, Wallentin L, Jernberg T. Relation between renal function, presentation, use of therapies and in-hospital complications in acute coronary syndrome: data from the SWEDEHEART register. J Intern Med 2010;268:40-49.
10. Ortiz A, Covic A, Fliser D, Fouque D, Goldsmith D, Kanbay M, Mallamaci F, Massy ZA, Rossignol P, Vanholder R, Wiecek A, Zoccali C, London GM. Epidemiology, contributors to, and clinical trials of mortality risk in chronic kidney failure. Lancet 2014;383:1831-1843.
11. Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, Wanner C, Krane V, Cass A, Craig J, Neal B, Jiang L, Hooi LS, Levin A, Agodoa L, Gaziano M, Kasiske B, Walker R, Massy ZA, Feldt-Rasmussen B, Krairittichai U, Ophascharoensuk V, Fellstrom B, Holdaas H, Tesar V, Wiecek A, Grobbee D, de ZD, Gronhagen-Riska C, Dasgupta T, Lewis D, Herrington W, Mafham M, Majoni W, Wallendszus K, Grimm R, Pedersen T, Tobert J, Armitage J, Baxter A, Bray C, Chen Y, Chen Z, Hill M, Knott C, Parish S, Simpson D, Sleight P, Young A, Collins R. The effects of lowering LDL cholesterol with simvastatin plus ezeti-mibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011;377:2181-2192.
12. Chertow GM, Block GA, Correa-Rotter R, Drueke TB, Floege J, Goodman WG, Herzog CA, Kubo Y, London GM, Mahaffey KW, Mix TC, Moe SM, Trotman ML, Wheeler DC, Parfrey PS. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med 2012;367:2482-2494.
13. Verheugt FW, Clemmensen P, Mehran R, Agewall S, Pocock SJ, Goldstein S, Torp-Pedersen C, Simoons ML, Borer JS, Khder YM, Burton P, Deliargyris E, McMurray JJ, Berkowitz SD, Stough WG, Zannad F. Antithrombotic outcome trials in acute coronary syndromes: seeking the optimal balance between safety and efficacy. Eur Heart J 2013;34:1621-1629.
14. Zannad F, Garcia AA, Anker SD, Armstrong PW, Calvo G, Cleland JG, Cohn JN, Dickstein K, Domanski MJ, Ekman I, Filippatos GS, Gheorghiade M, Hernandez AF, Jaarsma T, Koglin J, Konstam M, Kupfer S, Maggioni AP, Mebazaa A, Metra M, Nowack C, Pieske B, Pina IL, Pocock SJ, Ponikowski P, Rosano G, Ruilope LM, Ruschitzka F, Severin T, Solomon S, Stein K, Stockbridge NL, Stough WG, Swedberg K, Tavazzi L, Voors AA, Wasserman SM, Woehrle H, Zalewski A, McMurray JJ. Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document. Eur J Heart Fail 2013;15:1082-1094.
15. Bansal N, Hyre AA, Yang W, Christenson RH, deFilippi CR, Deo R, Dries DL, Go AS, He J, Kusek JW, Lash JP, Raj D, Rosas S, Wolf M, Zhang X, Shlipak MG, Feldman HI. High-sensitivity troponin T and N-terminal pro-B-type natriuretic peptide (NT-proBNP) and risk of incident heart failure in patients with CKD: the Chronic Renal Insufficiency Cohort (CRIC) Study. J Am Soc Nephrol 2015;26:946-956.
16. Chawla LS, Herzog CA, Costanzo MR, Tumlin J, Kellum JA, McCullough PA, Ronco C. Proposal for a functional classification system of heart failure in patients with end-stage renal disease: proceedings of the acute dialysis quality initiative (ADQI) XI workgroup. J Am Coll Cardiol 2014;63:1246-1252.
17. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, Flachskampf FA, Foster E, Goldstein SA, Kuznetsova T, Lancellotti P, Muraru D, Picard MH, Rietzschel ER, Rudski L, Spencer KT, Tsang W, Voigt JU. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2015;28:1-39.
18. Sandoval Y, Herzog CA, Love SA, Cao J, Hu Y, Wu AH, Gilbertson D, Brunelli SM, Young A, Ler R, Apple FS. Prognostic value of serial changes in high-sensitivity cardiac troponin I and T over 3 months using reference change values in hemodialysis patients. Clin Chem 2016;62:631-638.
19. Hicks KA, Tcheng JE, Bozkurt B, Chaitman BR, Cutlip DE, Farb A, Fonarow GC, Jacobs JP, Jaff MR, Lichtman JH, Limacher MC, Mahaffey KW, Mehran R, Nissen SE, Smith EE, Targum SL. 2014 ACC/AHA key data elements and definitions for cardiovascular endpoint events in clinical trials: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards). J Am Coll Cardiol 2015;66:403-469.
20. Rossignol P, Pitt B, Thompson A, Zannad F. A roadmap to design future cardiovascular prevention trials in chronic kidney disease. Lancet 2016;388: 1964-1966.
21. Braunschweig F, Kjellstrom B, Soderhall M, Clyne N, Linde C. Dynamic changes in right ventricular pressures during haemodialysis recorded with an implantable haemodynamic monitor. Nephrol Dial Transplant 2006;21:176-183.
22. Kjellstrom B, Braunschweig F, Lofberg E, Fux T, Grandjean PA, Linde C. Changes in right ventricular pressures between hemodialysis sessions recorded by an implantable hemodynamic monitor. Am J Cardiol 2009;103:119-123.
23. Stacy SR, Suarez-Cuervo C, Berger Z, Wilson LM, Yeh HC, Bass EB, Michos ED. Role of troponin in patients with chronic kidney disease and suspected acute coronary syndrome A systematic review. Ann Intern Med 2014;161:502-512.
24. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, Thygesen K, Alpert JS, White HD, Jaffe AS, Katus HA, Apple FS, Lindahl B, Morrow DA, Chaitman BA, Clemmensen PM, Johanson P, Hod H, Underwood R, Bax JJ, Bonow RO, Pinto F, Gibbons RJ, Fox KA, Atar D, Newby LK, Galvani M, Hamm CW, Uretsky BF, Steg PG, Wijns W, Bassand JP, Menasche P, Ravkilde J, Ohman EM, Antman EM, Wallentin LC, Armstrong PW, Simoons ML, Januzzi JL, Nieminen MS, Gheorghiade M, Filippatos G, Luepker RV, Fortmann SP, Rosamond WD, Levy D, Wood D, Smith SC, Hu D, Lopez-Sendon JL, Robertson RM, Weaver D, Tendera M, Bove AA, Parkhomenko AN, Vasilieva EJ, Mendis S. Third universal definition of myocardial infarction. Eur Heart J 2012;33:2551-2567.
25. Pocock SJ, Clayton TC, Stone GW. Design of major randomized trials: part 3 of a 4-part series on statistics for clinical trials. J Am Coll Cardiol 2015;66:2757-2766.
26. Anker SD, Agewall S, Borggrefe M, Calvert M, Jaime CJ, Cowie MR, Ford I, Paty JA, Riley JP, Swedberg K, Tavazzi L, Wiklund I, Kirchhof P. The importance of patient-reported outcomes: a call for their comprehensive integration in cardio-vascular clinical trials. Eur Heart J 2014;35:2001-2009.
27. Anker SD, Schroeder S, Atar D, Bax JJ, Ceconi C, Cowie MR, Crisp A, Dominjon F, Ford I, Ghofrani HA, Gropper S, Hindricks G, Hlatky MA, Holcomb R, Honarpour N, Jukema JW, Kim AM, Kunz M, Lefkowitz M, Le FC, Landmesser U, McDonagh TA, McMurray JJ, Merkely B, Packer M, Prasad K, Revkin J, Rosano GM, Somaratne R, Stough WG, Voors AA, Ruschitzka F. Traditional and new composite endpoints in heart failure clinical trials: facilitating comprehensive efficacy assessments and improving trial efficiency. Eur J Heart Fail 2016;18:482-489.
28. Janssen Research and Development. Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy (CREDENCE) (NCT02065791). https://clinicaltrials.gov/ct2/show/NCT02065791 (1 November 2016)
29. Amorim LD, Cai J. Modelling recurrent events: a tutorial for analysis in epidemiology. Int J Epidemiol 2015;44:324-333.
30. Pogue J, Devereaux PJ, Thabane L, Yusuf S. Designing and analyzing clinical trials with composite outcomes: consideration of possible treatment differences between the individual outcomes. PLoS One 2012;7:e34785.
31. Stafinski T, Menon D, Nardelli A, Bakal J, Ezekowitz J, Tymchak W, Welsh R, Gyenes G, Armstrong PW. Incorporating patient preferences into clinical trial design: results of the opinions of patients on treatment implications of new studies (OPTIONS) project. Am Heart J 2015;169:122-131.
32. Canaud B, Hegbrant J, Nissenson AR, Barth C, Maddux F, Etter M, Krishnan M. Improving outcomes of dialysis patients by population health management-the Global Chief Medical Officer Initiative. Lancet 2016;388:1966-1967.